Pierre O Chappuis

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Risk assessment & genetic testing
    Pierre O Chappuis
    Division of Medical Genetics, Department of Medicine, McGill University Health Center, Montreal, QC, Canada
    Cancer Treat Res 107:29-59. 2002
  2. ncbi request reprint [Colorectal cancer: a risk-adapted screening and the role of the physician in the prevention of this cancer]
    P O Chappuis
    Service d Oncologie, Service de Genetique Medicale, HUG, 1211 Geneve 14
    Rev Med Suisse 2:1314, 1316, 1318-23. 2006
  3. ncbi request reprint [Breast cancer screening different from that used for the general population: who is concerned and with which approach?]
    P O Chappuis
    Service d oncologie et Service de génétique médicale HUG, 1211 Geneve 14
    Rev Med Suisse 2:1296-8, 1301-2, 1304-5. 2006
  4. ncbi request reprint [Plea for the family history...in the area of molecular oncology]
    Pierre O Chappuis
    Unité d identification des predispositions génétiques au cancer, Service d Oncologie, Departement de Medecine Interne, HUG, 1211 Geneve 14
    Rev Med Suisse 1:1368-71, 1373. 2005
  5. ncbi request reprint Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment
    P O Chappuis
    Department of Human Genetics, McGill University, Montreal, QC, Canada
    Ann Oncol 16:735-42. 2005
  6. pmc A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
    Mark E Robson
    Research Institute of McGill University Health Centre, Cancer Prevention Centre, McGill University, Montreal, Quebec, Canada
    Breast Cancer Res 6:R8-R17. 2004
  7. ncbi request reprint The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer
    William D Foulkes
    Program in Cancer Genetics and Department of Oncology, Research Institute of the McGill University Health Centre, and Cancer Prevention Centre, Sir M B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Cancer Res 64:830-5. 2004
  8. doi request reprint Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases
    David J Novak
    Departments of Oncology and Human Genetics, Program in Cancer Genetics, McGill University, Montreal, QC, Canada H2W 1S6
    Breast Cancer Res Treat 117:453-9. 2009
  9. ncbi request reprint Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
    William D Foulkes
    Program in Cancer Genetics, Department of Oncology and Human Genetics, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Natl Cancer Inst 95:1482-5. 2003
  10. ncbi request reprint Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data
    John R Goffin
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Cancer 97:527-36. 2003

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Risk assessment & genetic testing
    Pierre O Chappuis
    Division of Medical Genetics, Department of Medicine, McGill University Health Center, Montreal, QC, Canada
    Cancer Treat Res 107:29-59. 2002
    ..Predictive oncology is best performed by a dedicated unit with professionals aware of all the issues surrounding genetic testing...
  2. ncbi request reprint [Colorectal cancer: a risk-adapted screening and the role of the physician in the prevention of this cancer]
    P O Chappuis
    Service d Oncologie, Service de Genetique Medicale, HUG, 1211 Geneve 14
    Rev Med Suisse 2:1314, 1316, 1318-23. 2006
    ..Molecular screening for the main colorectal cancer predisposing genes should now be integrated in the clinical management of these patients and their families...
  3. ncbi request reprint [Breast cancer screening different from that used for the general population: who is concerned and with which approach?]
    P O Chappuis
    Service d oncologie et Service de génétique médicale HUG, 1211 Geneve 14
    Rev Med Suisse 2:1296-8, 1301-2, 1304-5. 2006
    ..Screening with magnetic resonance imaging (MRI) is recommended only for women identified as high risk. Genetic testing of the main breast cancer susceptibility genes, BRCA1 and BRCA2, is now available in a clinical setting...
  4. ncbi request reprint [Plea for the family history...in the area of molecular oncology]
    Pierre O Chappuis
    Unité d identification des predispositions génétiques au cancer, Service d Oncologie, Departement de Medecine Interne, HUG, 1211 Geneve 14
    Rev Med Suisse 1:1368-71, 1373. 2005
    ..Specific screening and preventive strategies are recommended in the management of these high risk individuals...
  5. ncbi request reprint Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment
    P O Chappuis
    Department of Human Genetics, McGill University, Montreal, QC, Canada
    Ann Oncol 16:735-42. 2005
    ..The relationship between cyclin E/p27(Kip1) levels, BRCA1 status and outcome has not been studied in detail...
  6. pmc A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
    Mark E Robson
    Research Institute of McGill University Health Centre, Cancer Prevention Centre, McGill University, Montreal, Quebec, Canada
    Breast Cancer Res 6:R8-R17. 2004
    ..The prognostic significance of germline mutations in BRCA1 and BRCA2 in women with breast cancer remains unclear. A combined analysis was performed to address this uncertainty...
  7. ncbi request reprint The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer
    William D Foulkes
    Program in Cancer Genetics and Department of Oncology, Research Institute of the McGill University Health Centre, and Cancer Prevention Centre, Sir M B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Cancer Res 64:830-5. 2004
    ..Basal breast cancer deserves recognition as an important subtype of breast cancer...
  8. doi request reprint Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases
    David J Novak
    Departments of Oncology and Human Genetics, Program in Cancer Genetics, McGill University, Montreal, QC, Canada H2W 1S6
    Breast Cancer Res Treat 117:453-9. 2009
    ..Conclusions Overall, it seems unlikely that moderate to highly penetrant alleles of either RAP80 or Abraxas, confer a significantly high relative risk of breast cancer...
  9. ncbi request reprint Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
    William D Foulkes
    Program in Cancer Genetics, Department of Oncology and Human Genetics, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Natl Cancer Inst 95:1482-5. 2003
    ..0, 95% confidence interval = 1.9 to 43; P =.002, two-sided Fisher's exact test). Thus, germline BRCA1 mutations appear to be associated with a distinctive breast cancer phenotype...
  10. ncbi request reprint Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data
    John R Goffin
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Cancer 97:527-36. 2003
    ..The joint effect of both abnormalities has not been studied. The primary objective of this study was to assess the impact of germline BRCA1 mutations and p53 overexpression on survival after 10 years of follow-up...
  11. ncbi request reprint Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma
    William D Foulkes
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Cancer 98:1569-77. 2003
    ..Therefore, the authors questioned whether the known positive correlation between tumor size and lymph node status also was present in women with BRCA1-related breast carcinomas...
  12. ncbi request reprint The influence of familial and hereditary factors on the prognosis of breast cancer
    P O Chappuis
    Department of Medicine, McGill University, Montreal, Quebec, Canada
    Ann Oncol 10:1163-70. 1999
    ..The recent identification of breast cancer predisposing genes has provided new clinical insights in this field...
  13. ncbi request reprint Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
    W D Foulkes
    Department of Medicine, Sir M B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Ann Oncol 11:307-13. 2000
    ..The association between BRCA1 germ-line mutations and breast cancer prognosis is controversial. A historical cohort study was designed to determine the prognosis for women with axillary lymph node negative hereditary breast cancer...
  14. ncbi request reprint [Epigenetics and cancer]
    I Kern
    Service de pédiatri, HUG, 1211 Geneve 14
    Rev Med Suisse 3:540-2, 544-5. 2007
    ..Thus, epigenetic inhibitors are currently evaluated as anticancer drugs. Moreover, DNA methylation study holds promise as biological marker for classification, diagnostic and prognostic purposes in clinical practice...
  15. ncbi request reprint Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer
    P O Chappuis
    McGill University Health Centre Research Institute, McGill University, Montreal, Quebec, Canada
    Clin Genet 59:418-23. 2001
    ..The absence of BRCA1 mutations may be a result of chance, but may also reflect different geographical origins of the most common BRCA1 mutations within the French Canadian population...
  16. ncbi request reprint Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer
    P O Chappuis
    Department of Medicine, Montreal General Hospital, McGill University, Montreal, Quebec, Canada
    Semin Surg Oncol 18:287-95. 2000
    ..The probability of finding a BRCA1/2 germ-line mutation is partly determined by these characteristics. In addition, these features will likely influence the behavior of BRCA1/2-related breast cancer...
  17. ncbi request reprint The contribution of inherited factors to the clinicopathological features and behavior of breast cancer
    W D Foulkes
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    J Mammary Gland Biol Neoplasia 6:453-65. 2001
    ..Here, we outline some of the clinicopathological features of hereditary breast cancer, discuss the prognostic studies that have been performed, and introduce some possible new research directions...
  18. ncbi request reprint The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update
    P O Chappuis
    Division of Medical Genetics, Department of Medicine, McGill University, Montreal General Hospital, Montreal, QC, Canada
    Cancer Invest 19:65-75. 2001
    ..The real challenge for the management of high risk patients is to develop new screening methods than can identify pre-neoplastic or early neoplastic lesions in a timely manner...
  19. ncbi request reprint Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients
    Anna M Russell
    Research Group Human Genetics, Division of Medical Genetics, Center for Biomedicine, University of Basel, Basel, Switzerland
    Int J Cancer 118:1937-40. 2006
    ....
  20. ncbi request reprint Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer
    Jarle B Arnes
    Department of Pathology, The Gade Institute, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 11:4003-11. 2005
    ..BRCA1-related breast cancer frequently has a basal epithelial phenotype, and P-cadherin is a basal marker. We undertook a detailed evaluation of the relationship among P-cadherin, prognostic markers in breast cancer, and outcome...
  21. doi request reprint Increased risk of second cancer among patients with ovarian borderline tumors
    Christine Bouchardy
    Geneva Cancer Registry, Institute of Social and Preventive Medicine, Geneva University, Geneva, Switzerland
    Gynecol Oncol 109:210-4. 2008
    ..Such risk has not been investigated for ovarian borderline tumors. We aim to evaluate the risk of subsequent cancer occurrence among patients with borderline ovarian tumors in a population-based setting...
  22. ncbi request reprint Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis
    Elisabetta Rapiti
    Geneva Cancer Registry, Institute for Social and Preventive Medicine, University of Geneva
    J Clin Oncol 24:2743-9. 2006
    ..In this population-based study, we evaluate the impact of local surgery on survival of patients with metastatic breast cancer at diagnosis...
  23. ncbi request reprint Survival after bilateral breast cancer: results from a population-based study
    Helena M Verkooijen
    Geneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University, 55 bd de la Cluse, CH 1205, Geneva, Switzerland
    Breast Cancer Res Treat 105:347-57. 2007
    ..Controversy exists on the impact of bilaterality of breast cancer on survival. We used population-based data to compare survival of women with unilateral versus bilateral breast cancer...
  24. ncbi request reprint Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers
    Oddbjørn Straume
    Department of Pathology, The Gade Institute, University of Bergen, Bergen 5021, Norway
    Cancer Res 62:6808-11. 2002
    ..02), and was a better predictor of outcome than was microvessel density. In conclusion, GMPs might indicate a more aggressive vascular phenotype associated with poor prognosis and could be a novel prognostic marker in human cancer...
  25. ncbi request reprint Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study
    Helena M Verkooijen
    Geneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University, Geneva, Switzerland
    Int J Cancer 122:1114-7. 2008
    ..This excess risk is largely due to the increased risk of secondary chronic leukemia...
  26. ncbi request reprint Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status
    William D Foulkes
    J Natl Cancer Inst 94:1504-6. 2002